Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Peter M. Hecht sold 65,987 shares of the stock in a transaction that occurred on Thursday, January 12th. The shares were sold at an average price of $15.67, for a total transaction of $1,034,016.29. Following the transaction, the chief executive officer now owns 4,703,315 shares in the company, valued at $73,700,946.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) opened at 15.67 on Friday. The stock’s market cap is $2.29 billion. Ironwood Pharmaceuticals, Inc. has a 12-month low of $7.35 and a 12-month high of $16.89. The firm has a 50 day moving average of $15.59 and a 200-day moving average of $14.43.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, November 3rd. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. Ironwood Pharmaceuticals had a negative net margin of 34.29% and a negative return on equity of 94.17%. The firm had revenue of $66 million for the quarter, compared to the consensus estimate of $60.01 million. During the same period in the prior year, the firm earned ($0.25) EPS. The firm’s revenue for the quarter was up 66.7% on a year-over-year basis. On average, analysts expect that Ironwood Pharmaceuticals, Inc. will post ($0.75) earnings per share for the current year.

Insider Buying and Selling by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

TRADEMARK VIOLATION NOTICE: “Peter M. Hecht Sells 65,987 Shares of Ironwood Pharmaceuticals, Inc. (IRWD) Stock” was first reported by Watch List News and is the propert of of Watch List News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of US and international copyright and trademark laws. The legal version of this piece of content can be viewed at http://www.watchlistnews.com/peter-m-hecht-sells-65987-shares-of-ironwood-pharmaceuticals-inc-irwd-stock/1061236.html.

A number of large investors have recently made changes to their positions in IRWD. Strs Ohio acquired a new stake in shares of Ironwood Pharmaceuticals during the third quarter valued at $107,000. Joel Isaacson & Co. LLC purchased a new position in Ironwood Pharmaceuticals during the third quarter valued at approximately $109,000. Acrospire Investment Management LLC boosted its position in Ironwood Pharmaceuticals by 20.0% in the third quarter. Acrospire Investment Management LLC now owns 7,800 shares of the company’s stock valued at $124,000 after buying an additional 1,300 shares during the period. SG Americas Securities LLC purchased a new position in Ironwood Pharmaceuticals during the third quarter valued at approximately $127,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Ironwood Pharmaceuticals during the second quarter valued at approximately $144,000. 94.66% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently issued reports on IRWD shares. Zacks Investment Research downgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, September 20th. Mizuho dropped their price objective on shares of Ironwood Pharmaceuticals from $24.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, October 10th. Wedbush increased their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $13.00 and gave the company a “neutral” rating in a research note on Monday, October 24th. WallachBeth Capital increased their price objective on shares of Ironwood Pharmaceuticals from $15.00 to $17.00 and gave the company a “hold” rating in a research note on Tuesday, September 27th. Finally, BTIG Research reiterated a “buy” rating and set a $18.00 price objective (up from $15.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, September 23rd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $15.64.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.

5 Day Chart for NASDAQ:IRWD

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.